709 related articles for article (PubMed ID: 33377903)
21. Prediction of cervical intraepithelial neoplasia grade 2+ (CIN2+) using HPV DNA testing after a diagnosis of atypical squamous cell of undetermined significance (ASC-US) in Catalonia, Spain.
Ibáñez R; Moreno-Crespi J; Sardà M; Autonell J; Fibla M; Gutiérrez C; Lloveras B; Alejo M; Català I; Alameda F; Casas M; Bosch FX; de Sanjosé S
BMC Infect Dis; 2012 Jan; 12():25. PubMed ID: 22280073
[TBL] [Abstract][Full Text] [Related]
22. Cervical screening with primary HPV testing or cytology in a population of women in which those aged 33 years or younger had previously been offered HPV vaccination: Results of the Compass pilot randomised trial.
Canfell K; Caruana M; Gebski V; Darlington-Brown J; Heley S; Brotherton J; Gertig D; Jennett CJ; Farnsworth A; Tan J; Wrede CD; Castle PE; Saville M
PLoS Med; 2017 Sep; 14(9):e1002388. PubMed ID: 28926579
[TBL] [Abstract][Full Text] [Related]
23. Risk of high-grade cervical intra-epithelial neoplasia based on cytology and high-risk HPV testing at baseline and at 6-months.
Bulk S; Bulkmans NW; Berkhof J; Rozendaal L; Boeke AJ; Verheijen RH; Snijders PJ; Meijer CJ
Int J Cancer; 2007 Jul; 121(2):361-7. PubMed ID: 17354241
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of 14 triage strategies for HPV DNA-positive women in population-based cervical screening.
Rijkaart DC; Berkhof J; van Kemenade FJ; Coupe VM; Hesselink AT; Rozendaal L; Heideman DA; Verheijen RH; Bulk S; Verweij WM; Snijders PJ; Meijer CJ
Int J Cancer; 2012 Feb; 130(3):602-10. PubMed ID: 21400507
[TBL] [Abstract][Full Text] [Related]
25. Performance of standardised colposcopy to detect cervical precancer and cancer for triage of women testing positive for human papillomavirus: results from the ESTAMPA multicentric screening study.
Valls J; Baena A; Venegas G; Celis M; González M; Sosa C; Santin JL; Ortega M; Soilán A; Turcios E; Figueroa J; Rodríguez de la Peña M; Figueredo A; Beracochea AV; Pérez N; Martínez-Better J; Lora O; Jiménez JY; Giménez D; Fleider L; Salgado Y; Martínez S; Bellido-Fuentes Y; Flores B; Tatti S; Villagra V; Cruz-Valdez A; Terán C; Sánchez GI; Rodríguez G; Picconi MA; Ferrera A; Mendoza L; Calderón A; Murillo R; Wiesner C; Broutet N; Luciani S; Pérez C; Darragh TM; Jerónimo J; Herrero R; Almonte M;
Lancet Glob Health; 2023 Mar; 11(3):e350-e360. PubMed ID: 36796982
[TBL] [Abstract][Full Text] [Related]
26. Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test.
Ronco G; Giorgi-Rossi P; Carozzi F; Confortini M; Dalla Palma P; Del Mistro A; Gillio-Tos A; Minucci D; Naldoni C; Rizzolo R; Schincaglia P; Volante R; Zappa M; Zorzi M; Cuzick J; Segnan N;
J Natl Cancer Inst; 2008 Apr; 100(7):492-501. PubMed ID: 18364502
[TBL] [Abstract][Full Text] [Related]
27. Prospective cohort study examining cervical cancer screening methods in HIV-positive and HIV-negative Cambodian Women: a comparison of human papilloma virus testing, visualization with acetic acid and digital colposcopy.
Thay S; Goldstein A; Goldstein LS; Govind V; Lim K; Seang C
BMJ Open; 2019 Feb; 9(2):e026887. PubMed ID: 30804036
[TBL] [Abstract][Full Text] [Related]
28. Triage by methylation-marker testing versus cytology in women who test HPV-positive on self-collected cervicovaginal specimens (PROHTECT-3): a randomised controlled non-inferiority trial.
Verhoef VM; Bosgraaf RP; van Kemenade FJ; Rozendaal L; Heideman DA; Hesselink AT; Bekkers RL; Steenbergen RD; Massuger LF; Melchers WJ; Bulten J; Overbeek LI; Berkhof J; Snijders PJ; Meijer CJ
Lancet Oncol; 2014 Mar; 15(3):315-22. PubMed ID: 24529697
[TBL] [Abstract][Full Text] [Related]
29. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study.
Castle PE; Stoler MH; Wright TC; Sharma A; Wright TL; Behrens CM
Lancet Oncol; 2011 Sep; 12(9):880-90. PubMed ID: 21865084
[TBL] [Abstract][Full Text] [Related]
30. [Three-year follow-up results of visual inspection with acetic acid/Lugol's iodine (VIA/VILI) used as an alternative screening method for cervical cancer in rural areas].
Zhang YZ; Ma JF; Zhao FH; Xiang XE; Ma ZH; Shi YT; Hu SY; Qiao YL
Chin J Cancer; 2010 Jan; 29(1):4-8. PubMed ID: 20038302
[TBL] [Abstract][Full Text] [Related]
31. Comparison of Hybrid capture 2 testing at different thresholds with cytology as primary cervical screening test.
Rijkaart DC; Coupe VM; van Kemenade FJ; Heideman DA; Hesselink AT; Verweij W; Rozendaal L; Verheijen RH; Snijders PJ; Berkhof J; Meijer CJ
Br J Cancer; 2010 Sep; 103(7):939-46. PubMed ID: 20808310
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of partial genotyping with HPV16/18 for triage of HPV positive, cytology negative women in the COMPACT study.
Hanley SJB; Fujita H; Aoyama-Kikawa S; Kasamo M; Torigoe T; Matsuno Y; Noriaki S;
J Gynecol Oncol; 2021 Nov; 32(6):e86. PubMed ID: 34708593
[TBL] [Abstract][Full Text] [Related]
33. Pooled analysis of a self-sampling HPV DNA Test as a cervical cancer primary screening method.
Zhao FH; Lewkowitz AK; Chen F; Lin MJ; Hu SY; Zhang X; Pan QJ; Ma JF; Niyazi M; Li CQ; Li SM; Smith JS; Belinson JL; Qiao YL; Castle PE
J Natl Cancer Inst; 2012 Feb; 104(3):178-88. PubMed ID: 22271765
[TBL] [Abstract][Full Text] [Related]
34. Extension of cervical screening intervals with primary human papillomavirus testing: observational study of English screening pilot data.
Rebolj M; Cuschieri K; Mathews CS; Pesola F; Denton K; Kitchener H;
BMJ; 2022 May; 377():e068776. PubMed ID: 35640960
[TBL] [Abstract][Full Text] [Related]
35. Triaging HPV-positive, cytology-negative cervical cancer screening results with extended HPV genotyping and p16
Song F; Yan P; Huang X; Wang C; Qu X; Du H; Wu R
BMC Infect Dis; 2021 Apr; 21(1):400. PubMed ID: 33931022
[TBL] [Abstract][Full Text] [Related]
36. Primary HPV screening for cervical cancer: Results after two screening rounds in a regional screening program in Finland.
Veijalainen O; Kares S; Kotaniemi-Talonen L; Kujala P; Vuento R; Luukkaala T; Kholová I; Mäenpää J
Acta Obstet Gynecol Scand; 2021 Mar; 100(3):403-409. PubMed ID: 33037625
[TBL] [Abstract][Full Text] [Related]
37. Protocol for Compass: a randomised controlled trial of primary HPV testing versus cytology screening for cervical cancer in HPV-unvaccinated and vaccinated women aged 25-69 years living in Australia.
Canfell K; Saville M; Caruana M; Gebski V; Darlington-Brown J; Brotherton J; Heley S; Castle PE
BMJ Open; 2018 Jan; 8(1):e016700. PubMed ID: 29374658
[TBL] [Abstract][Full Text] [Related]
38. [Health technology assessment report. Use of liquid-based cytology for cervical cancer precursors screening].
Ronco G; Confortini M; Maccallini V; Naldoni C; Segnan N; Sideri M; Zappa M; Zorzi M; Calvia M; Giorgi Rossi P
Epidemiol Prev; 2012; 36(5 Suppl 2):e1-e33. PubMed ID: 23139163
[TBL] [Abstract][Full Text] [Related]
39. Effectiveness of high-risk human papillomavirus genotyping for cervical cancer screening. A multicentre screening cohort study in rural China.
Yu YQ; Jiang MY; Zhang X; Pan QJ; Dang L; Feng RM; Ali NM; Chen W; Qiao YL
An Sist Sanit Navar; 2024 May; 47(2):. PubMed ID: 38817086
[TBL] [Abstract][Full Text] [Related]
40. The WID-CIN test identifies women with, and at risk of, cervical intraepithelial neoplasia grade 3 and invasive cervical cancer.
Barrett JE; Sundström K; Jones A; Evans I; Wang J; Herzog C; Dillner J; Widschwendter M
Genome Med; 2022 Oct; 14(1):116. PubMed ID: 36258199
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
